Terry Fox Cancer Research Laboratories, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St John's, Newfoundland, Canada.
PLoS One. 2012;7(2):e32499. doi: 10.1371/journal.pone.0032499. Epub 2012 Feb 24.
MIER1 was originally identified in a screen for novel fibroblast growth factor activated early response genes. The mier1 gene gives rise to multiple transcripts encoding protein isoforms that differ in their amino (N-) and carboxy (C-) termini. Much of the work to date has focused on the two C-terminal variants, MIER1α and β, both of which have been shown to function as transcriptional repressors. Our previous work revealed a dramatic shift in MIER1α subcellular localization from nuclear in normal breast tissue to cytoplasmic in invasive breast carcinoma, suggesting that loss of nuclear MIER1α may play a role in breast cancer development. In the present study, we investigated whether alternative splicing to include a cassette exon and produce an N-terminal variant of MIER1α affects its subcellular localization in MCF7 breast carcinoma cells. We demonstrate that this cassette exon, exon 3A, encodes a consensus leucine-rich nuclear export signal (NES). Inclusion of this exon in MIER1α to produce the MIER1-3Aα isoform altered its subcellular distribution in MCF7 cells from 81% nuclear to 2% nuclear and this change in localization was abrogated by mutation of critical leucines within the NES. Treatment with leptomycin B (LMB), an inhibitor of the nuclear export receptor CRM1, resulted in a significant increase in the percentage of cells with nuclear MIER1-3Aα, from 4% to 53%, demonstrating that cytoplasmic localization of this isoform was due to CRM1-dependent nuclear export. Inclusion of exon 3A in MIER1β to produce the N-terminal variant MIER1-3Aβ however had little effect on the nuclear targeting of this isoform. Our results demonstrate that alternative splicing to include exon 3A specifically affects the localization pattern of the α isoform.
MIER1 最初是在筛选新的成纤维细胞生长因子激活的早期反应基因时发现的。mier1 基因产生多种转录本,编码在其氨基(N-)和羧基(C-)末端不同的蛋白同工型。迄今为止,大部分工作都集中在两种 C 末端变体 MIER1α 和 β 上,这两种变体都被证明具有转录抑制子的功能。我们之前的工作揭示了 MIER1α 的亚细胞定位从正常乳腺组织中的核内到浸润性乳腺癌中的细胞质的显著变化,这表明核内 MIER1α 的丢失可能在乳腺癌的发展中起作用。在本研究中,我们研究了是否通过选择性剪接包括一个盒式外显子并产生 MIER1α 的 N 末端变体来影响其在 MCF7 乳腺癌细胞中的亚细胞定位。我们证明了这个盒式外显子,外显子 3A,编码一个保守的亮氨酸丰富的核输出信号(NES)。将这个外显子纳入 MIER1α 中,产生 MIER1-3Aα 同工型,改变了其在 MCF7 细胞中的亚细胞分布,从 81%的核内到 2%的核内,并且这种定位的改变被 NES 内关键亮氨酸的突变所消除。用莱姆素 B(LMB)处理,一种核输出受体 CRM1 的抑制剂,导致核内 MIER1-3Aα 的细胞百分比显著增加,从 4%增加到 53%,证明了这种同工型的细胞质定位是由于 CRM1 依赖的核输出。然而,将外显子 3A 纳入 MIER1β 中以产生 N 末端变体 MIER1-3Aβ 对该同工型的核靶向几乎没有影响。我们的结果表明,选择性剪接包括外显子 3A 特异性地影响 α 同工型的定位模式。